<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131095">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01865877</url>
  </required_header>
  <id_info>
    <org_study_id>INNN 35/12</org_study_id>
    <secondary_id>182133</secondary_id>
    <nct_id>NCT01865877</nct_id>
  </id_info>
  <brief_title>Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study</brief_title>
  <acronym>ReMePARK</acronym>
  <official_title>Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</source>
  <oversight_info>
    <authority>Mexico: National Council of Science and Technology</authority>
    <authority>Mexico: Ethics Committee</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the effect of motor, non-motor and genetic factors
      on the progression of Parkinson's disease as well as its impact on complications rates.

      A large sample of Mexican subjects with Parkinson's disease attending several referral
      centers will be included.

      Data collected will include disease severity and motor scales, non-motor scales as well as
      genotyping for monogenic forms of the disease.

      Assessments will be performed every 6 months for two years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demographic and clinical data will be collected after obtaining a signed informed consent.

      Recruitment will be competitive. Data collected includes age, gender, motor phenotype, age
      at onset, age at diagnosis, smoking history, family history, antiparkinsonic treatment,
      other treatments and a complete neurological evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>To assess motor scale change over time</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Motor symptoms will be assessed by proper and validated motor scales; also minimal clinically important change will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess non-motor symptoms over time</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-motor symptoms will be assessed using proper validated scales. Frequency and severity will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life change over time.</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health-related quality of life will be assessed with proper validated clinimetric instruments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess caregiver burden as disease progresses</measure>
    <time_frame>Every 12 months for 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Caregiver burden will be assessed by proper validated scales.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the change in prevalence of neuropsychiatric symptoms over time</measure>
    <time_frame>Every 12 months for 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence and incidence of depression, apathy, cognitive decline, psychosis and impulse control disorder will be determined.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>PD Cohort</arm_group_label>
    <description>Subjects diagnosed with Parkinson's disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and/or saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with idiopathic or genetic Parkinson's disease attending any of the
        participant sites in Mexico.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Parkinson's disease by the United Kingdom Parkinson's disease Society
             Brain Bank Criteria

          -  Any gender

          -  Any Hoehn and Yahr stage

          -  Written informed consent

        Exclusion Criteria:

          -  Severe comorbidity that may limit proper neurological evaluation as judged by the
             investigator

          -  Subjects with atypical or secondary parkinsonism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin Cervantes-Arriaga, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Neurología y Neurocirugía</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amin Cervantes-Arriaga, MD,MSc</last_name>
    <phone>+525556063822</phone>
    <phone_ext>5018</phone_ext>
    <email>acervantes@innn.edu.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mayela Rodríguez-Violante, MD,MSc</last_name>
    <phone>+525556063822</phone>
    <phone_ext>5018</phone_ext>
    <email>mrodriguez@innn.edu.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Neurología y Neurocirugía</name>
      <address>
        <city>Mexico City</city>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Cervantes-Arriaga, MD,MSc</last_name>
      <phone>+5256063822</phone>
      <phone_ext>5018</phone_ext>
      <email>acervantes@innn.edu.mx</email>
    </contact>
    <investigator>
      <last_name>Mayela Rodríguez-Violante, MD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de México</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Español</name>
      <address>
        <city>Mexico City</city>
        <zip>11520</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.innn.salud.gob.mx</url>
    <description>Instituto Nacional de Neurología y Neurocirugía</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 28, 2013</lastchanged_date>
  <firstreceived_date>May 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</investigator_affiliation>
    <investigator_full_name>Amin Cervantes-Arriaga</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Motor</keyword>
  <keyword>Non-motor</keyword>
  <keyword>Progression</keyword>
  <keyword>Complications</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
